ALGS Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.

$1.35  +0.04 (3.05%)
As of 06/27/2022 16:00:01 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/16/2020
Outstanding shares:  42,695,195
Average volume:  328,276
Market cap:   $55,930,705
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BNGFS94

---

Valuation   (See tab for details)

---

PE ratio:   -0.41
PB ratio:   0.37
PS ratio:   9.29
Return on equity:   -89.13%
Net income %:   -2,263.64%